Nature of Glutamate Alterations in Schizophrenia: A Meta-analysis of Proton Magnetic Resonance Spectroscopy Studies
Open accessAbstract
IMPORTANCE: Alterations in glutamatergic neurotransmission may be fundamental to the pathophysiology of schizophrenia, and the glutamatergic system is a target for novel therapeutic interventions in the disorder. OBJECTIVE: To investigate the nature of brain glutamate alterations in schizophrenia by conducting a meta-analysis of glutamate proton magnetic resonance (MRS) spectroscopy studies. DATA SOURCES: The MEDLINE database was searched for studies published from January 1, 1980, to April 1, 2015. Search terms included magnetic resonance spectroscopy, schizophrenia, psychosis, clinical or genetic high risk, and schizoaffective. Inclusion criteria were single voxel 1H-MRS studies reporting glutamate, glutamine or Glx values for a patient or risk group in comparison to a healthy volunteer group. STUDY SELECTION: Fifty-nine studies were identified, which included 1686 patients and 1451 healthy individuals serving as controls. DATA EXTRACTION AND SYNTHESIS: A random-effects, inverse-weighted variance model was used to calculate the pooled effect size. Mean values were extracted and verified independently. Effect sizes were determined for glutamate, glutamine, and Glx in brain regions that had been examined in at least 3 different studies. A secondary analysis grouped studies into those examining patients at different stages of illness (high risk, first-episode psychosis, or chronic schizophrenia). Effects of age, antipsychotic dose, and symptom severity were determined using meta-regression. RESULTS: In schizophrenia, there were significant elevations in glutamate in the basal ganglia (Hedges g = 0.63; 95% CI, 0.15-1.11), glutamine in the thalamus (g = 0.56; 95% CI, 0.02-1.09), and Glx in the basal ganglia (g = 0.39; 95% CI, 0.09-0.70) and medial temporal lobe (g = 0.32; 95% CI, 0.12-0.52). No region showed a reduction in glutamate metabolites in schizophrenia. Secondary analyses revealed that elevated medial frontal Glx levels were evident in individuals at high risk for schizophrenia (g = 0.26; 95% CI, 0.05-0.46) but not in those with first-episode psychosis or chronic schizophrenia, whereas elevated Glx in the medial temporal lobe was seen with chronic schizophrenia (g = 0.40; 95% CI, 0.08-0.71) but not in the high-risk or first-episode groups. Meta-regression found no association with age, symptom severity, or antipsychotic dose. CONCLUSIONS AND RELEVANCE: Schizophrenia is associated with elevations in glutamatergic metabolites across several brain regions. This finding supports the hypothesis that schizophrenia is associated with excess glutamatergic neurotransmission in several limbic areas and further indicates that compounds that reduce glutamatergic transmission may have therapeutic potential.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Evidence from magnetic resonance spectroscopy suggests that alterations in glutamatergic neurotransmission may change over the course of schizophrenia.
“Evidence from magnetic resonance spectroscopy suggests that alterations in glutamatergic neurotransmission may change over the course of schizophrenia (96, 97).”
From The Predictive Coding Account of Psychosis (2018) · cites this paper as [96]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552 · see citing works
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378 · see citing works
Wasserman, S. S., Hedges, L. V., & Olkin, I. (1988) · Journal of Educational Statistics · doi:10.2307/1164953 · Cited by 10,347 · see citing works
Sterne, J. A. C., Sutton, A. J., Ioannidis, J. P. A., Terrin, N., Jones, D. R., Lau, J., Carpenter, J., Rucker, G., Harbord, R. M., Schmid, C. H., et al. (2011) · BMJ · doi:10.1136/bmj.d4002 · Cited by 7,709 · see citing works
Biological insights from 108 schizophrenia-associated genetic loci
Schizophrenia Working Group of the Psychiatric Genomics Consortium (2014) · Nature · doi:10.1038/nature13595 · Cited by 7,577 · see citing works
Recent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904 · see citing works
Statistical Methods for Meta-Analysis
(1985) · Elsevier eBooks · doi:10.1016/c2009-0-03396-0 · Cited by 2,549 · see citing works
Moghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793 · see citing works
Glutamate receptor dysfunction and schizophrenia
Olney, J. W. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950240016004 · Cited by 1,685 · see citing works
Lisman, J. E., Coyle, J. T., Green, R. W., Javitt, D. C., Benes, F. M., Heckers, S., & Grace, A. A. (2008) · Trends in Neurosciences · doi:10.1016/j.tins.2008.02.005 · Cited by 1,010 · see citing works
Kempton, M. J., Salvador, Z., Munafò, M. R., Geddes, J. R., Simmons, A., Frangou, S., & Williams, S. C. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.60 · Cited by 886 · see citing works
Self-citationGlutamate in Schizophrenia: A Focused Review and Meta-Analysis of 1H-MRS Studies
Marsman, A., van den Heuvel, M. P., Klomp, D. W. J., Kahn, R. S., Luijten, P. R., & Hulshoff Pol, H. E. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr069 · Cited by 457 · see citing works
Théberge, J., Bartha, R., Drost, D. J., Menon, R. S., MALLA, A. K., Takhar, J., Neufeld, R. W. J., Rogers, J. S., Pavlosky, W. F., Schaefer, B., et al. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.11.1944 · Cited by 398 · see citing works
Steiner, J. H., Walter, M., Glanz, W., Sarnyai, Z., Bernstein, H., Vielhaber, S., Kästner, A., Skalej, M., Jordan, W., Schiltz, K., et al. (2013) · JAMA Psychiatry · doi:10.1001/2013.jamapsychiatry.86 · Cited by 379 · see citing works
Hippocampal dysregulation of dopamine system function and the pathophysiology of schizophrenia
Lodge, D. J., & Grace, A. A. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.05.001 · Cited by 349 · see citing works
Demjaha, A., Egerton, A., Murray, R. M., Kapur, S., Howes, O. D., Stone, J. M., & McGuire, P. K. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.06.011 · Cited by 336 · see citing works
Mao, X. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.1519 · Cited by 296 · see citing works
<sup>13</sup> C MRS studies of neuroenergetics and neurotransmitter cycling in humans
Rothman, D. L., De Feyter, H. M., de Graaf, R. A., Mason, G. F., & Behar, K. L. (2011) · NMR in Biomedicine · doi:10.1002/nbm.1772 · Cited by 290 · see citing works
Abnormal Glutamatergic Neurotransmission and Neuronal-Glial Interactions in Acute Mania
Öngür, D., Jensen, J. E., Prescot, A. P., Stork, C., Lundy, M. Y., Cohen, B. M., & Renshaw, P. F. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.05.014 · Cited by 272 · see citing works
Théberge, J., Al-Semaan, Y. M., Williamson, P., Menon, R. S., Neufeld, R. W. J., Rajakumar, N., Schaefer, B., Densmore, M., & Drost, D. J. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.12.2231 · Cited by 269 · see citing works
de la Fuente-Sandoval, C., León-Ortíz, P., Favila, R., Stephano, S., Mamo, D., Ramírez-Bermúdez, J., & Graff-Guerrero, A. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.65 · Cited by 248 · see citing works
Stone, J. M., Day, F., Tsagaraki, H., Valli, I., McLean, M. A., Lythgoe, D. J., O'Gorman, R. L., Barker, G. J., & McGuire, P. K. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.05.006 · Cited by 231 · see citing works
Bartha, R. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830220085012 · Cited by 230 · see citing works
Increased Hippocampal Glutamate and Volumetric Deficits in Unmedicated Patients With Schizophrenia
Kraguljac, N. V., White, D. M., Reid, M. A., & Lahti, A. C. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.2437 · Cited by 191 · see citing works
Longitudinal grey-matter and glutamatergic losses in first-episode schizophrenia
Théberge, J., Williamson, K. E., Aoyama, N., Drost, D. J., Manchanda, R., Malla, A. K., Northcott, S., Menon, R. S., Neufeld, R. W. J., Rajakumar, N., et al. (2007) · British Journal of Psychiatry · doi:10.1192/bjp.bp.106.033670 · Cited by 185 · see citing works
de la Fuente‐Sandoval, C., León-Ortíz, P., Azcárraga, M., Stephano, S., Favila, R., Díaz-Galvis, L., Alvarado-Alanis, P., Ramírez‐Bermúdez, J., & Graff‐Guerrero, A. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.289 · Cited by 181 · see citing works
van Elst, L. T., Valerius, G., Büchert, M., Thiel, T., Rüsch, N., Bubl, E., Hennig, J., Ebert, D., & Olbrich, H. M. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.04.041 · Cited by 164 · see citing works
1H-MRS at 4 Tesla in minimally treated early schizophrenia
Bustillo, J. R., Rowland, L. M., Mullins, P., Jung, R., Chen, H., Qualls, C., Hammond, R., Brooks, W. M., & Lauriello, J. (2010) · Molecular Psychiatry · doi:10.1038/mp.2009.121 · Cited by 153 · see citing works
Tibbo, P. G., Hanstock, C. C., Valiakalayil, A., & Allen, P. S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.6.1116 · Cited by 152 · see citing works
GABA and glutamate in schizophrenia: A 7 T 1H-MRS study
Marsman, A., Mandl, R. C. W., Klomp, D. W. J., Bohlken, M. M., Boer, V. O., Андрейченко, А. Е., Cahn, W., Kahn, R. S., Luijten, P. R., & Pol, H. E. H. (2014) · NeuroImage Clinical · doi:10.1016/j.nicl.2014.10.005 · Cited by 151 · see citing works
In Vivo Measurements of Glutamate, GABA, and NAAG in Schizophrenia
Rowland, L. M., Kontson, K. L., West, J., Edden, R. A. E., Zhu, H., Wijtenburg, S. A., Holcomb, H. H., & Barker, P. B. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs092 · Cited by 150 · see citing works
Elevated Gamma-Aminobutyric Acid Levels in Chronic Schizophrenia
Öngür, D., Prescot, A. P., McCarthy, J. M., Cohen, B. M., & Renshaw, P. F. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.05.016 · Cited by 144 · see citing works
White Matter Alterations in Deficit Schizophrenia
Rowland, L. M., Spieker, E. A., Francis, A., Barker, P. B., Carpenter, W. T., & Buchanan, R. W. (2008) · Neuropsychopharmacology · doi:10.1038/npp.2008.207 · Cited by 144 · see citing works
Proton MRS in twin pairs discordant for schizophrenia
Lutkenhoff, E. S., van Erp, T. G., Thomas, M. A., Therman, S., Manninen, M., HUTTUNEN, M. O., Kaprio, J. A., Lönnqvist, J. K., O’Neill, J., & Cannon, T. D. (2008) · Molecular Psychiatry · doi:10.1038/mp.2008.87 · Cited by 127 · see citing works
Equipercentile linking of the BPRS and the PANSS
Leucht, S., Rothe, P., Davis, J. M., & Engel, R. R. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.11.004 · Cited by 126 · see citing works
Ohrmann, P., Siegmund, A., Suslow, T., Pedersen, A., Spitzberg, K., Kersting, A., Rothermundt, M., Arolt, V., Heindel, W., & Pfleiderer, B. (2007) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2006.07.002 · Cited by 116 · see citing works
Wood, S. J., Kennedy, D., Phillips, L., Seal, M. L., Yücel, M., Nelson, B., Yung, A. R., Jackson, G. D., McGorry, P. D., Velakoulis, D., et al. (2010) · NeuroImage · doi:10.1016/j.neuroimage.2010.04.012 · Cited by 114 · see citing works
Tayoshi, S., Sumitani, S., Taniguchi, K., Shibuya‐Tayoshi, S., Numata, S., Iga, J., Nakataki, M., Ueno, S., Harada, M., & Ohmori, T. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.11.014 · Cited by 111 · see citing works
Shirayama, Y., Obata, T., Matsuzawa, D., Nonaka, H., Kanazawa, Y., Yoshitome, E., Ikehira, H., Hashimoto, K., & Iyo, M. (2009) · NeuroImage · doi:10.1016/j.neuroimage.2009.10.031 · Cited by 103 · see citing works
Chang, L., Friedman, J. I., Ernst, T., Zhong, K., Tsopelas, N. D., & Davis, K. L. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.025 · Cited by 101 · see citing works
Ohrmann, P., Siegmund, A., Suslow, T., Spitzberg, K., Kersting, A., Arolt, V., Heindel, W. L., & Pfleiderer, B. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2004.08.021 · Cited by 100 · see citing works
Natsubori, T., Inoue, H., Abe, O., Takano, Y., Iwashiro, N., Aoki, Y. Y., Koike, S., Yahata, N., Katsura, M., Gonoi, W., et al. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbt124 · Cited by 100 · see citing works
Relationship between Glutamate Dysfunction and Symptoms and Cognitive Function in Psychosis
Merritt, K., McGuire, P. K., & Egerton, A. (2013) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2013.00151 · Cited by 100 · see citing works
An In Vivo Proton Magnetic Resonance Spectroscopy Study of Schizophrenia Patients
Stanley, J. A., Williamson, P., Drost, D. J., Rylett, R. J., Carr, T. J., MALLA, A. K., & Thompson, R. T. (1996) · Schizophrenia Bulletin · doi:10.1093/schbul/22.4.597 · Cited by 98 · see citing works
Terpstra, M., Vaughan, T. J., Uǧurbil, K., Lim, K. O., Schulz, S. C., & Rolf Gruetter, A. (2005) · Magnetic Resonance Materials in Physics Biology and Medicine · doi:10.1007/s10334-005-0012-0 · Cited by 95 · see citing works
Bustillo, J., Chen, H., Gasparovic, C., Mullins, P. G., Caprihan, A., Qualls, C., Apfeldorf, W. J., Lauriello, J., & Posse, S. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.08.024 · Cited by 94 · see citing works
Hippocampal pathology in schizophrenia: magnetic resonance imaging and spectroscopy studies
Kegeles, L. S., Shungu, D. C., Anjilvel, S., Chan, S. L., Ellis, S. P., Xanthopoulos, E. P., Malaspina, D., Gorman, J. M., Mann, J. J., Laruelle, M., et al. (2000) · Psychiatry Research Neuroimaging · doi:10.1016/s0925-4927(00)00044-5 · Cited by 88 · see citing works
Egerton, A., Stone, J. M., Chaddock, C. A., Barker, G. J., Bonoldi, I., Howard, R. M., Merritt, K., Allen, P., Howes, O. D., Murray, R. M., et al. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.143 · Cited by 85 · see citing works
Regional Decoupling of N-acetyl-aspartate and Glutamate in Schizophrenia
Kraguljac, N. V., Reid, M. A., White, D. M., den Hollander, J., & Lahti, A. C. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.126 · Cited by 84 · see citing works
Increased Glutamine in Patients Undergoing Long-term Treatment for Schizophrenia
Bustillo, J., Chen, H., Jones, T., Lemke, N. T., Abbott, C., Qualls, C., Cañive, J. M., & Gasparovic, C. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.3939 · Cited by 82 · see citing works
N-Acetylaspartylglutamate (NAAG) and N-Acetylaspartate (NAA) in Patients With Schizophrenia
Jessen, F., Fingerhut, N., Sprinkart, A. M., Kühn, K.-U., Petrovsky, N., Maier, W., Schild, H. H., Block, W., Wagner, M., & Träber, F. (2011) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr127 · Cited by 82 · see citing works
Choe, B., Suh, T. S., Shinn, K.-S., Lee, C., Lee, C., & Paik, I. (1996) · Investigative Radiology · doi:10.1097/00004424-199606000-00006 · Cited by 79 · see citing works
Stan, A. D., Ghose, S., Zhao, C., Hulsey, K., Mihalakos, P., Yanagi, M., Morris, S., Bartko, J. J., Choi, C., & Tamminga, C. A. (2014) · Molecular Psychiatry · doi:10.1038/mp.2014.54 · Cited by 78 · see citing works
Bartha, R., Al-Semaan, Y. M., Williamson, P., Drost, D. J., MALLA, A. K., Carr, T. J., Densmore, M., Canaran, G., & Neufeld, R. W. J. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00007-4 · Cited by 77 · see citing works
Yoo, S. Y., Yeon, S., Choi, C., Kang, D.-H., Lee, J., Shin, N. Y., Jung, W. H., Choi, J., Jang, D., & Kwon, J. S. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.03.036 · Cited by 76 · see citing works
Snyder, J., & Wilman, A. H. (2009) · Journal of Magnetic Resonance · doi:10.1016/j.jmr.2009.12.002 · Cited by 75 · see citing works
Block, W., Bayer, T. A., Tepest, R., Träber, F., Rietschel, M., Müller, D. J., Schulze, T. G., Honer, W. G., Maier, W., Schild, H. H., et al. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01264-7 · Cited by 71 · see citing works
Ohrmann, P., Kugel, H., Bauer, J., Siegmund, A., Kölkebeck, K., Suslow, T., Wiedl, K. H., Rothermundt, M., Arolt, V., & Pedersen, A. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.08.005 · Cited by 70 · see citing works
Tandon, N., Bolo, N. R., Sanghavi, K., Mathew, I. T., Francis, A., Stanley, J. A., & Keshavan, M. S. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.05.024 · Cited by 68 · see citing works
Purdon, S. E., Valiakalayil, A., Hanstock, C. C., Seres, P., & Tibbo, P. G. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2007.11.028 · Cited by 67 · see citing works
Hutcheson, N. L., Reid, M. A., White, D. M., Kraguljac, N. V., Avsar, K. B., Bolding, M., Knowlton, R. C., den Hollander, J. A., & Lahti, A. C. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.06.039 · Cited by 65 · see citing works
Choe, B., Kim, K. T., Suh, T. S., Lee, C., Paik, I., Bahk, Y.-W., Shinn, K.-S., & Lenkinski, R. E. (1994) · Academic Radiology · doi:10.1016/s1076-6332(05)80716-0 · Cited by 64 · see citing works
Preliminary study of frontal lobe 1H MR spectroscopy in childhood‐onset schizophrenia
Thomas, M. A., Ke, Y., Levitt, J. G., Caplan, R., Curran, J. G., Asarnow, R. F., & McCracken, J. T. (1998) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.1880080413 · Cited by 61 · see citing works
Wood, S. J., Yücel, M., Wellard, R. M., Harrison, B. J., Clarke, K., Fornito, A., Velakoulis, D., & Pantelis, C. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.05.008 · Cited by 60 · see citing works
Keshavan, M. S., Dick, R. M., Diwadkar, V. A., Montrose, D. M., Prasad, K. M. R., & Stanley, J. A. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.08.012 · Cited by 59 · see citing works
Yoshimura, R., Gotō, N., Kakeda, S., Nishimura, J., Moriya, J., Hayashi, K., Hori, H., Ikenouchi, A., Umen-Nakano, W., Katsuki, A., et al. (2012) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s25582 · Cited by 58 · see citing works
Wood, S. J., Berger, G. E., Wellard, R. M., Proffitt, T., McConchie, M., Velakoulis, D., McGorry, P. D., & Pantelis, C. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.03.012 · Cited by 56 · see citing works
Proton Magnetic Resonance Spectroscopy in 22q11 Deletion Syndrome
Alves, F. D. S., Boot, E., Schmitz, N., Nederveen, A. J., Vorstman, J. A. S., Lavini, C., Pouwels, P. J. W., de Haan, L., LINSZEN, D. H., & van Amelsvoort, T. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021685 · Cited by 51 · see citing works
Szulc, A., Galińska-Skok, B., Tarasów, E., Waszkiewicz, N., Konarzewska, B., Popławska, R., Bibulowicz, D., Simonienko, K., & Walecki, J. M. (2011) · Pharmacopsychiatry · doi:10.1055/s-0031-1279739 · Cited by 51 · see citing works
Galińska-Skok, B., Szulc, A., Tarasów, E., Kubas, B., Dzienis, W., Czernikiewicz, A., & Walecki, J. M. (2009) · PubMed · Cited by 50 · see citing works
Stanley, J. A., Vemulapalli, M., Nutche, J. J., Montrose, D. M., Sweeney, J. A., Pettegrew, J. W., MacMaster, F. P., & Keshavan, M. S. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.03.028 · Cited by 44 · see citing works
Hippocampal integrity and neurocognition in first-episode schizophrenia: A multidimensional study
Hasan, A., Wobrock, T., Falkai, P., Schneider-Axmann, T., Guse, B., Backens, M., Ecker, U. K. H., Heimes, J., Galea, J. M., Gruber, O., et al. (2011) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2011.620002 · Cited by 43 · see citing works
Tunc‐Skarka, N., Weber‐Fahr, W., Hoerst, M., Meyer‐Lindenberg, A., Zink, M., & Ende, G. (2009) · NeuroImage · doi:10.1016/j.neuroimage.2009.06.061 · Cited by 34 · see citing works
3‐T proton magnetic spectroscopy in unmedicated first episode psychosis: A focus on creatine
Tibbo, P. G., Bernier, D. C., Hanstock, C. C., Seres, P., Lakusta, B., & Purdon, S. E. (2012) · Magnetic Resonance in Medicine · doi:10.1002/mrm.24291 · Cited by 33 · see citing works
Proton magnetic resonance spectroscopy and thought disorder in childhood schizophrenia
Seese, R. R., O’Neill, J., Hudkins, M. R., Siddarth, P., Levitt, J. G., Tseng, B., Wu, K. N., & Caplan, R. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.07.011 · Cited by 30 · see citing works
Glutamatergic changes in the cerebral white matter associated with schizophrenic exacerbation
Ota, M., Ishikawa, M., Sato, N., Hori, H., Sasayama, D., Hattori, K., Teraishi, T., Nakata, Y., & Kunugi, H. (2012) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2012.01853.x · Cited by 29 · see citing works
Capizzano, A. A., Toscano, J. L. N., & Ho, B. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.05.024 · Cited by 25 · see citing works
Bloemen, O., Gleich, T., de Koning, M. B., Alvis, F. D. S., de Haan, L., LINSZEN, D. H., Booij, J., & van Amelsvoort, T. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.11.030 · Cited by 24 · see citing works
Yamasue, H., Fukui, T., Fukuda, R., Kasai, K., Iwanami, A., Kato, N., & Kato, T. (2003) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145703003687 · Cited by 17 · see citing works
Flagged first, then by citations
3 of the 82 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Szulc A, Galinska B, Tarasów E, et al. Glutamatergic system dysfunction in schizophrenia: a proton magnetic resonance spectroscopy ( 1 H MRS) study. Pol J Radiol. 2004;69(1):33-36.
Cited by
Sorted by citations
The Predictive Coding Account of Psychosis
Sterzer, P., Adams, R. A., Fletcher, P., Frith, C., Lawrie, S. M., Muckli, L., Petrovic, P., Uhlhaas, P., Voss, M., & Corlett, P. R. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2018.05.015 · Cited by 941 · see citing works
“Evidence from magnetic resonance spectroscopy suggests that alterations in glutamatergic neurotransmission may change over the course of schizophrenia (95,96).”
BackgroundCognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment
McCutcheon, R. A., Keefe, R. S. E., & McGuire, P. K. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-01949-9 · Cited by 800 · see citing works
Dopamine and glutamate in schizophrenia: biology, symptoms and treatment
McCutcheon, R. A., Krystal, J. H., & Howes, O. D. (2020) · World Psychiatry · doi:10.1002/wps.20693 · Cited by 612 · see citing works
Prevention of Psychosis: Advances in Detection, Prognosis, and Intervention
Fusar-Poli, P., Salazar de Pablo, G., Correll, C. U., Meyer-Lindenberg, A., Millan, M. J., Borgwardt, S., Galderisi, S., Bechdolf, A., Pfennig, A., Kessing, L. V., et al. (2020) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2019.4779 · Cited by 476 · see citing works
Glutamate hypothesis in schizophrenia
Uno, Y., & Coyle, J. T. (2019) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12823 · Cited by 371 · see citing works
Neurofilaments: neurobiological foundations for biomarker applications
Gafson, A., Barthélemy, N. R., Bomont, P., Carare, R. O., Durham, H. D., Julien, J., Kühle, J., Leppert, D., Nixon, R. A., Weller, R. O., et al. (2020) · Brain · doi:10.1093/brain/awaa098 · Cited by 327 · see citing works
The blood–brain barrier in psychosis
Pollak, T. A., Drndarski, S., Stone, J. M., David, A. S., McGuire, P. K., & Abbott, N. J. (2017) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30293-6 · Cited by 304 · see citing works
Blood-brain barrier regulation in psychiatric disorders
Kealy, J., Greene, C., & Campbell, M. (2018) · Neuroscience Letters · doi:10.1016/j.neulet.2018.06.033 · Cited by 307 · see citing works
Neuroimaging Biomarkers in Schizophrenia
Kraguljac, N. V., McDonald, W. M., Widge, A. S., Rodríguez, C. I., Tohen, M. F., & Nemeroff, C. B. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20030340 · Cited by 244 · see citing works
Oxidative Stress‐Related Mechanisms in Schizophrenia Pathogenesis and New Treatment Perspectives
Ermakov, E. A., Dmitrieva, E. M., Parshukova, D. A., Kazantseva, D. V., Vasilieva, A. R., & Smirnova, L. P. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/8881770 · Cited by 252 · see citing works
Smucny, J., Dienel, S. J., Lewis, D. A., & Carter, C. S. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-021-01089-0 · Cited by 231 · see citing works
Molecular targets of atypical antipsychotics: From mechanism of action to clinical differences
Aringhieri, S., Carli, M., Kolachalam, S., Verdesca, V., Cinì, E., Rossi, M., McCormick, P., Corsini, G., Maggio, R., & Scarselli, M. (2018) · Pharmacology and Therapeutics · doi:10.1016/j.pharmthera.2018.06.012 · Cited by 182 · see citing works
Altered gut microbiota and mucosal immunity in patients with schizophrenia
Xu, R., Wu, B., Liang, J., He, F., Gu, W., Li, K., Luo, Y., Chen, J., Gao, Y., Wu, Z., et al. (2020) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2019.06.039 · Cited by 198 · see citing works
Mitochondria, Metabolism, and Redox Mechanisms in Psychiatric Disorders
Kim, Y., Vadodaria, K. C., Lenkei, Z., Kato, T., Gage, F. H., Marchetto, M. C., & Santos, R. (2018) · Antioxidants and Redox Signaling · doi:10.1089/ars.2018.7606 · Cited by 189 · see citing works
Grent-‘t-Jong, T., Groß, J., Goense, J. B. M., Wibral, M., Gajwani, R., Gumley, A. I., Lawrie, S. M., Schwannauer, M., Schultze‐Lutter, F., Schröder, T. N., et al. (2018) · eLife · doi:10.7554/elife.37799 · Cited by 161 · see citing works
Neuroimaging studies of GABA in schizophrenia: a systematic review with meta-analysis
Egerton, A., Modinos, G., Ferrera, D., & McGuire, P. K. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.124 · Cited by 164 · see citing works
Li, C.-T., Yang, K.-C., & Lin, W.-C. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00767 · Cited by 147 · see citing works
Wang, A. M., Pradhan, S., Coughlin, J. M., Trivedi, A. M., DuBois, S. L., Crawford, J. L., Sedlak, T. W., Nucifora, F. C., Nestadt, G., Nucifora, L. G., et al. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.3637 · Cited by 158 · see citing works
Nakahara, T., Tsugawa, S., Noda, Y., Ueno, F., Honda, S., Kinjo, M., Segawa, H., Hondo, N., Mori, Y., Watanabe, H., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01297-6 · Cited by 157 · see citing works
Glutathione and glutamate in schizophrenia: a 7T MRS study
Kumar, J., Liddle, E. B., Fernandes, C. C., Palaniyappan, L. K., Hall, E. L., Robson, S. E., Simmonite, M., Jan, F., Katshu, M. Z. U. H., Qureshi, A., et al. (2018) · Molecular Psychiatry · doi:10.1038/s41380-018-0104-7 · Cited by 154 · see citing works
Glutamatergic dysfunction in Schizophrenia
Kruse, A. O., & Bustillo, J. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02253-w · Cited by 154 · see citing works
Keshavan, M. S., Collin, G., Guimond, S., Kelly, S., Prasad, K. M. R., & Lizano, P. L. (2019) · Neuroimaging Clinics of North America · doi:10.1016/j.nic.2019.09.007 · Cited by 152 · see citing works
Molina, J. L., Voytek, B., Thomas, M. L., Joshi, Y. B., Bhakta, S. G., Talledo, J., Swerdlow, N. R., & Light, G. A. (2020) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2020.02.004 · Cited by 153 · see citing works
Pál, B. Z. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2837-5 · Cited by 135 · see citing works
Liu, Y., Ouyang, P., Zheng, Y., Mi, L., Zhao, J., Ning, Y., & Guo, W. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.664535 · Cited by 129 · see citing works
Egerton, A., Broberg, B. V., van Haren, N. E. M., Merritt, K., Barker, G. J., Lythgoe, D. J., Pérez‐Iglesias, R., Baandrup, L., Düring, S. W., Sendt, K.-V., et al. (2018) · Molecular Psychiatry · doi:10.1038/s41380-018-0082-9 · Cited by 127 · see citing works
Current findings and perspectives on aberrant neural oscillations in schizophrenia
Hirano, Y., & Uhlhaas, P. J. (2021) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13300 · Cited by 121 · see citing works
Iwata, Y., Nakajima, S., Plitman, E., Caravaggio, F., Kim, J., Shah, P., Mar, W., Chavez, S., Luca, V. D., Mimura, M., et al. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2018.09.009 · Cited by 121 · see citing works
Emerging Evidence for the Widespread Role of Glutamatergic Dysfunction in Neuropsychiatric Diseases
McGrath, T., Baskerville, R., Rogero, M. M., & Castell, L. M. (2022) · Nutrients · doi:10.3390/nu14050917 · Cited by 120 · see citing works
Heinz, A., Murray, G. K., Schlagenhauf, F., Sterzer, P., Grace, A. A., & Waltz, J. A. (2018) · Schizophrenia Bulletin · doi:10.1093/schbul/sby154 · Cited by 118 · see citing works
Jauhar, S., McCutcheon, R., Borgan, F., Veronese, M., Nour, M., Pepper, F., Rogdaki, M., Stone, J., Egerton, A., Turkheimer, F., et al. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(18)30268-2 · Cited by 114 · see citing works
Glutamate in schizophrenia: Neurodevelopmental perspectives and drug development
Egerton, A., Grace, A. A., Stone, J. M., Bossong, M. G., Sand, M. S., & McGuire, P. K. (2020) · Schizophrenia Research · doi:10.1016/j.schres.2020.09.013 · Cited by 113 · see citing works
Spatial and temporal boundaries of NMDA receptor hypofunction leading to schizophrenia
Nakazawa, K., Jeevakumar, V., & Nakao, K. (2017) · npj Schizophrenia · doi:10.1038/s41537-016-0003-3 · Cited by 110 · see citing works
Javitt, D. C., Carter, C. S., Krystal, J. H., Kantrowitz, J. T., Girgis, R. R., Kegeles, L. S., Ragland, J. D., Maddock, R. J., Lesh, T. A., Tanase, C., et al. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.3572 · Cited by 100 · see citing works
Cognition and Reward Circuits in Schizophrenia: Synergistic, Not Separate
Robison, A. J., Thakkar, K. N., & Diwadkar, V. A. (2019) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.09.021 · Cited by 101 · see citing works
Dempster, K., Jeon, P., Mackinley, M., Williamson, P., Théberge, J., & Palaniyappan, L. K. (2020) · Molecular Psychiatry · doi:10.1038/s41380-020-0704-x · Cited by 94 · see citing works
Interactions between central nervous system and peripheral metabolic organs
Zeng, W., Yang, F., Shen, W. L., Zhan, C., Zheng, P., & Hu, J. (2022) · Science China Life Sciences · doi:10.1007/s11427-021-2103-5 · Cited by 96 · see citing works
Thalamus-related anomalies as candidate mechanism-based biomarkers for psychosis
Steullet, P. (2019) · Schizophrenia Research · doi:10.1016/j.schres.2019.05.027 · Cited by 90 · see citing works
Egerton, A., Murphy, A., Donocik, J. G., Anton, A., Barker, G. J., Collier, T., Deakin, J. F. W., Drake, R., Eliasson, E. T., Emsley, R., et al. (2020) · Schizophrenia Bulletin · doi:10.1093/schbul/sbaa128 · Cited by 90 · see citing works
Halff, E. F., Rutigliano, G., Garcia-Hidalgo, A., & Howes, O. D. (2022) · Trends in Neurosciences · doi:10.1016/j.tins.2022.10.010 · Cited by 90 · see citing works
Roalf, D. R., Nanga, R. P. R., Rupert, P. E., Hariharan, H., Quarmley, M., Calkins, M. E., Dress, E. M., Prabhakaran, K., Elliott, M. A., Moberg, P. J., et al. (2017) · Molecular Psychiatry · doi:10.1038/mp.2016.258 · Cited by 89 · see citing works
Antioxidant Properties of Second-Generation Antipsychotics: Focus on Microglia
Caruso, G., Grasso, M., Fidilio, A., Tascedda, F., Drago, F., & Caraci, F. (2020) · Pharmaceuticals · doi:10.3390/ph13120457 · Cited by 88 · see citing works
Egerton, A., Bhachu, A., Merritt, K., McQueen, G., Szulc, A., & McGuire, P. K. (2017) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2017.00066 · Cited by 84 · see citing works
Bossong, M. G., Antoniades, M., Azis, M., Samson, C., Quinn, B., Bonoldi, I., Modinos, G., Perez, J., Howes, O. D., Stone, J. M., et al. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.3252 · Cited by 81 · see citing works
Variability and magnitude of brain glutamate levels in schizophrenia: a meta and mega-analysis
Merritt, K., McCutcheon, R. A., Aleman, A., Ashley, S. A., Beck, K., Block, W., Bloemen, O., Borgan, F., Boules, C., Bustillo, J., et al. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-01991-7 · Cited by 82 · see citing works
A Neural “Tuning Curve” for Multisensory Experience and Cognitive-Perceptual Schizotypy
Ferri, F., Nikolova, Y. S., Perrucci, M. G., Costantini, M., Ferretti, A., Gatta, V., Huang, Z., Edden, R. A. E., Yue, Q., D’Aurora, M., et al. (2016) · Schizophrenia Bulletin · doi:10.1093/schbul/sbw174 · Cited by 74 · see citing works
de la Fuente‐Sandoval, C., Reyes-Madrigal, F., Mao, X., León-Ortíz, P., Rodríguez-Mayoral, O., Jung-Cook, H. H., Solís‐Vivanco, R., Graff‐Guerrero, A., & Shungu, D. C. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.09.028 · Cited by 73 · see citing works
In Vivo Availability of Cannabinoid 1 Receptor Levels in Patients With First-Episode Psychosis
Borgan, F., Laurikainen, H., Veronese, M., Marques, T. R., Haaparanta‐Solin, M., Solin, O. H., Dahoun, T., Rogdaki, M., Salokangas, R. K. R., Karukivi, M., et al. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2019.1427 · Cited by 73 · see citing works
Increasing Nrf2 Activity as a Treatment Approach in Neuropsychiatry
Morris, G., Walker, A. J., Walder, K. R., Berk, M., Marx, W., Carvalho, A. F., Maes, M. H. J., & Puri, B. K. (2021) · Molecular Neurobiology · doi:10.1007/s12035-020-02212-w · Cited by 74 · see citing works
Changes in Brain Glutamate on Switching to Clozapine in Treatment-Resistant Schizophrenia
McQueen, G., Sendt, K.-V., Gillespie, A. L., Avila, A., Lally, J., Vallianatou, K., Chang, N., Ferreira, D., Borgan, F., Howes, O. D., et al. (2020) · Schizophrenia Bulletin · doi:10.1093/schbul/sbaa156 · Cited by 69 · see citing works
Duarte, J. M. N., & Xin, L. (2018) · Neurochemical Research · doi:10.1007/s11064-018-2521-z · Cited by 69 · see citing works
Sydnor, V. J., & Roalf, D. R. (2020) · Schizophrenia Research · doi:10.1016/j.schres.2020.06.028 · Cited by 68 · see citing works
Toward recovery in schizophrenia: Current concepts, findings, and future research directions
Onitsuka, T., Hirano, Y., Nakazawa, T., Ichihashi, K., Miura, K., Inada, K., Mitoma, R., Yasui‐Furukori, N., & Hashimoto, R. (2022) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13342 · Cited by 70 · see citing works
Astrocytic Regulation of Glutamate Transmission in Schizophrenia
Mei, Y.-Y., Wu, D., & Zhou, N. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00544 · Cited by 64 · see citing works
Kiemes, A., Davies, C., Kempton, M. J., Lukow, P. B., Bennallick, C., Stone, J. M., & Modinos, G. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.644315 · Cited by 65 · see citing works
Onwordi, E. C., Whitehurst, T., Mansur, A., Statton, B., Berry, A., Quinlan, M., O’Regan, D. P., Rogdaki, M., Marques, T. R., Rabiner, E. A., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01515-3 · Cited by 55 · see citing works
Kostova, R., Cecere, R., Thut, G., & Uhlhaas, P. J. (2020) · Schizophrenia Research · doi:10.1016/j.schres.2020.03.002 · Cited by 65 · see citing works
Nagai, T., Kirihara, K., Tada, M., Koshiyama, D., Koike, S., Suga, M., Araki, T., Hashimoto, K., & Kasai, K. (2017) · Scientific Reports · doi:10.1038/s41598-017-02267-1 · Cited by 61 · see citing works
Tarumi, R., Tsugawa, S., Noda, Y., Plitman, E., Honda, S., Matsushita, K., Chavez, S., Sawada, K., Wada, M., Matsui, M., et al. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0589-z · Cited by 56 · see citing works
Iwata, Y., Nakajima, S., Plitman, E., Mihashi, Y., Caravaggio, F., Chung, J. K., Kim, J., Gerretsen, P., Mimura, M., Remington, G. J., et al. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.03.016 · Cited by 60 · see citing works
Haarsma, J., Knolle, F., Griffin, J. D., Taverne, H., Mada, M., Goodyer, I. M., The NSPN Consortium, Fletcher, P. C., & Murray, G. K. (2020) · Journal of Abnormal Psychology · doi:10.1037/abn0000494 · Cited by 60 · see citing works
Bianciardi, B., & Uhlhaas, P. J. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.02.005 · Cited by 60 · see citing works
Duan, C., Cosgrove, J., & Deligiannidis, K. M. (2017) · Current Psychiatry Reports · doi:10.1007/s11920-017-0824-4 · Cited by 59 · see citing works
Goh, K. K., Wu, T., Chen, C.-H., & Lu, M. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120965937 · Cited by 54 · see citing works
Prestwood, T. R., Asgariroozbehani, R., Wu, S., Agarwal, S. M., Logan, R. W., Ballon, J. S., Hahn, M., & Freyberg, Z. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.113101 · Cited by 58 · see citing works
Approaches to neuromodulation for schizophrenia
Gault, J., Davis, R. A., Cascella, N. G., Saks, E. R., Corripio, I., Anderson, W. S., D, A. O. M., Thompson, J. A., Pomarol‐Clotet, E., Sawa, A., et al. (2017) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2017-316946 · Cited by 56 · see citing works
Anterior Cingulate Glutamate and GABA Associations on Functional Connectivity in Schizophrenia
Shukla, D. K., Wijtenburg, S. A., Chen, H., Chiappelli, J., Kochunov, P., Hong, L. E., & Rowland, L. M. (2018) · Schizophrenia Bulletin · doi:10.1093/schbul/sby075 · Cited by 52 · see citing works
Pillinger, T., Rogdaki, M., McCutcheon, R. A., Hathway, P., Egerton, A., & Howes, O. D. (2019) · Psychopharmacology · doi:10.1007/s00213-019-5188-5 · Cited by 53 · see citing works
Adaptive baseline fitting for MR spectroscopy analysis
Wilson, M. (2020) · Magnetic Resonance in Medicine · doi:10.1002/mrm.28385 · Cited by 53 · see citing works
Yuan, A., Veeranna, Sershen, H. W., Basavarajappa, B. S., Smiley, J. F., Hashim, A., Bleiwas, C., Berg, M. J., Guifoyle, D. N., Subbanna, S., et al. (2018) · Translational Psychiatry · doi:10.1038/s41398-018-0194-7 · Cited by 52 · see citing works
GABAergic System Dysfunction and Challenges in Schizophrenia Research
Jahangir, M., Zhou, J., Lang, B., & Wang, X. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.663854 · Cited by 52 · see citing works
Das, T. K., Dey, A., Sabesan, P., Javadzadeh, A., Théberge, J., Raduà, J., & Palaniyappan, L. K. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00438 · Cited by 49 · see citing works
Smucny, J., Carter, C. S., & Maddock, R. J. (2021) · Biological Psychiatry · doi:10.1016/j.biopsych.2021.06.008 · Cited by 50 · see citing works
Trends in big data analyses by multicenter collaborative translational research in psychiatry
Onitsuka, T., Hirano, Y., Nemoto, K., Hashimoto, N., Kushima, I., Koshiyama, D., Koeda, M., Takahashi, T., Noda, Y., Matsumoto, J., et al. (2021) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13311 · Cited by 49 · see citing works
Gomes, J. S., Trevizol, A. P., Ducos, D. V., Gadelha, A., Ortiz, B. B., Fonseca, A. O., Akiba, H. T., de Azevedo, C. C., Guimarães, L. S. P., Shiozawa, P., et al. (2018) · Schizophrenia Research Cognition · doi:10.1016/j.scog.2018.02.003 · Cited by 48 · see citing works
Wenneberg, C., Glenthoj, B. Y., Hjorthøj, C. R., Zingenberg, F. J. B., Glenthøj, L. B., Rostrup, E., Broberg, B. V., & Nordentoft, M. (2019) · Schizophrenia Research · doi:10.1016/j.schres.2019.10.050 · Cited by 46 · see citing works
Molecular imaging of schizophrenia: Neurochemical findings in a heterogeneous and evolving disorder
Cumming, P. D., Abi‐Dargham, A., & Gründer, G. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.113004 · Cited by 50 · see citing works
The influence of the glutamatergic system on cognition in schizophrenia: A systematic review
Thomas, E. H. X., Bozaoglu, K., Rossell, S. L., & Gurvich, C. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.04.005 · Cited by 47 · see citing works
Kim, S.-Y., Kaufman, M. J., Cohen, B. M., Jensen, J. E., Coyle, J. T., Du, F., & Öngür, D. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.08.022 · Cited by 47 · see citing works
Mehta, M. A., Schmechtig, A., Kotoula, V., McColm, J., Jackson, K. A., Brittain, C. F., Tauscher‐Wisniewski, S., Kinon, B. J., Morrison, P. D., Pollak, T. A., et al. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4877-9 · Cited by 47 · see citing works
Xu, M. K., Guo, Y., Cheng, J., Xue, K., Yang, M., Song, X., Feng, Y., & Cheng, J. (2021) · NeuroImage Clinical · doi:10.1016/j.nicl.2021.102736 · Cited by 47 · see citing works
Frontostriatothalamic effective connectivity and dopaminergic function in the psychosis continuum
Sabaroedin, K., Razi, A., Chopra, S., Tran, N., Pozaruk, A., Chen, Z., Finlay, A., Nelson, B., Allott, K., Álvarez‐Jiménez, M., et al. (2022) · Brain · doi:10.1093/brain/awac018 · Cited by 45 · see citing works
Kani, A. S., Shinn, A. K., Lewandowski, K. E., & Öngür, D. (2016) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2016.10.012 · Cited by 46 · see citing works
Sami, M. B., & Bhattacharyya, S. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118760662 · Cited by 45 · see citing works
Decreased Brain pH and Pathophysiology in Schizophrenia
Park, H. J., Choi, I., & Leem, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168358 · Cited by 46 · see citing works
Shakory, S., Watts, J. J., Hafizi, S., Silva, T. M. S., Khan, S. M., Michael Kiang, A., Bagby, R. M., Chavez, S., & Mizrahi, R. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0163-0 · Cited by 44 · see citing works
Kraguljac, N. V., Morgan, C. J., Reid, M. A., White, D. M., Jindal, R. D., Sivaraman, S., Martinak, B. K., & Lahti, A. C. (2019) · Schizophrenia Research · doi:10.1016/j.schres.2018.12.028 · Cited by 44 · see citing works
Allen, P., Sommer, I. E., Jardri, R., Eysenck, M. W., & Hugdahl, K. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.02.004 · Cited by 41 · see citing works
Schoonover, K. E., Dienel, S. J., & Lewis, D. A. (2020) · Biomarkers in Neuropsychiatry · doi:10.1016/j.bionps.2020.100015 · Cited by 44 · see citing works
Wang, M., Barker, P. B., Cascella, N. G., Coughlin, J. M., Nestadt, G., Nucifora, F. C., Sedlak, T. W., Kelly, A., Laurent Younes, B., Geman, D., et al. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-01969-5 · Cited by 44 · see citing works
Neurofunctional correlates of glutamate and GABA imbalance in psychosis: A systematic review
Zahid, U., Onwordi, E. C., Hedges, E. P., Wall, M. B., Modinos, G., Murray, R. M., & Egerton, A. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.105010 · Cited by 43 · see citing works
Ultra-High-Field Magnetic Resonance Spectroscopy in Psychiatry
Godlewska, B. R., Clare, S., Cowen, P. J., & Emir, U. E. (2017) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2017.00123 · Cited by 42 · see citing works
Disrupted Intersubject Variability Architecture in Functional Connectomes in Schizophrenia
Sun, X., Liu, J., Ma, Q., Duan, J., Wang, X., Xu, Y., Xu, Z., Ke Cheng, X. U., Wang, F., Tang, Y., et al. (2020) · Schizophrenia Bulletin · doi:10.1093/schbul/sbaa155 · Cited by 42 · see citing works
Mehta, M. A., & Hawkins, P. C. T. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-820480-1.00068-1 · Cited by 42 · see citing works
Balanced translocation linked to psychiatric disorder, glutamate, and cortical structure/function
Thomson, P. A., Duff, B. J., Blackwood, D., Romaniuk, L., Watson, A., Whalley, H. C., Li, X., Dauvermann, M. R., Moorhead, T. W. J., Bois, C., et al. (2016) · Schizophrenia · doi:10.1038/npjschz.2016.24 · Cited by 41 · see citing works
Efficacy of Memantine in Schizophrenic Patients: A Systematic Review
Iorio, G. D., Baroni, G., Lorusso, M., Montemitro, C., Spano, M. C., & Giannantonio, M. D. (2017) · Journal of Amino Acids · doi:10.1155/2017/7021071 · Cited by 41 · see citing works
Overbeek, G., Gawne, T. J., Reid, M. A., Salibi, N., Kraguljac, N. V., White, D. M., & Lahti, A. C. (2018) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2018.10.002 · Cited by 39 · see citing works
Wijtenburg, S. A., Wang, M., Korenic, S. A., Chen, S., Barker, P. B., & Rowland, L. M. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.656459 · Cited by 41 · see citing works
Ćurĉić‐Blake, B., Bais, L., Sibeijn‐Kuiper, A., Pijnenborg, H. M., Knegtering, H., Liemburg, E. J., & Aleman, A. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.05.020 · Cited by 40 · see citing works
Stone, J. M., Morrison, P. D., Koychev, I. G., Gao, F., Reilly, T. J., Kolanko, M., Mohammadinasab, A., Kapur, S., & McGuire, P. K. (2016) · Psychological Medicine · doi:10.1017/s0033291716002245 · Cited by 38 · see citing works
- Authors
- Merritt, K., Egerton, A., Kempton, M. J., Taylor, M. J., & McGuire, P. K.
- Affiliations
- King's College London (GB)
- Corresponding author
- Merritt, Kate
- Venue
- JAMA Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2016-07-01
- Volume
- 73
- Issue
- 7
- Pages
- 665
- ISSN
- 2168-622X (ISSN-L)
- OpenAlex
- W2424710696
- Cited by
- 367
- References
- 82
- Citations by year
- 2026: 26 · 2025: 23 · 2024: 25 · 2023: 37 · 2022: 33 · 2021: 50 · 2020: 55 · 2019: 44 · 2018: 41 · 2017: 28 · 2016: 5
- FWCI
- 34.95
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion, other-oa)
- Funders
- National Institute for Health and Care Research
- King's College London
- Medical Research Council (MR/L003988/1, MR/J008915/1)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Advanced MRI Techniques and Applications
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- schizophrenia, glutamate, glutamine, glutamatergic neurotransmission, basal ganglia, thalamus, medial temporal lobe, medial frontal cortex, first-episode psychosis, clinical high risk for psychosis, chronic schizophrenia, schizoaffective disorder, antipsychotic dosing, symptom severity, neuroimaging biomarkers
- MeSH terms
- Brain, Brain Mapping, Glutamine, Humans, Synaptic Transmission, Reference Values, Risk Factors, Schizophrenia, Glutamic Acid, Genetic Predisposition to Disease, Proton Magnetic Resonance Spectroscopy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
